Ulcerative Colitis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Age range: 18 - 70 years old, gender not restricted; (2) Meet the diagnostic criteria for ulcerative colitis, diagnosed through colonoscopy and pathological examination; (3) The condition is in the mild-to-moderate active stage, with a modified Mayo score ranging from 2 to 8; (4) Currently receiving standard treatment with mesalazine monotherapy, with a stable medication regimen for >= 4 weeks; (5) Able to understand and cooperate with this study, and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Age less than 18 years old or more than 70 years old; (2) Patients with severe active ulcerative colitis, or with severe complications such as intestinal perforation, massive bleeding, intestinal obstruction, etc.; (3) Pregnant women, lactating women, or those planning to become pregnant; (4) Known to be allergic to nuts, or with a body mass index (BMI) less than 18 kg/m^2; (5) Severely weak due to illness or medical procedures, or currently taking drugs that are contraindicated with calorie-restricted diets; (6) With diabetes and using hypoglycemic drugs that may increase the risk of hypoglycemia (such as insulin, sulfonylureas); (7) With a history of severe heart disease (uncompensated congestive heart failure NYHA grade 2 or above, left ventricular ejection fraction < 40%), syncope history, or with life-threatening malignant tumors; (8) Currently undergoing other calorie-restricted diets, or with a history of short bowel syndrome, small intestine/large intestine ostomy, total colectomy, etc. of gastrointestinal surgeries; (9) With liver or kidney dysfunction (ALT/AST more than 2 times the upper limit of normal value, serum creatinine more than 1.5 times the upper limit of normal value), which may be adversely affected by low-sugar and low-protein diets; (10) Participating in other clinical studies, or researchers consider other reasons not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Blood Count;Erythrocyte Sedimentation Rate;C-reactive protein;Fecal Calprotectin;Inflammatory factor;Endoscopic findings; | — |
Countries
China
Contacts
Tianjin Medical University General Hospital